SDGR:NSD-Schrodinger Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 19.73

Change

-0.03 (-0.15)%

Market Cap

USD 1.52B

Volume

0.21M

Analyst Target

USD 86.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

+0.08 (+0.10%)

USD 37.81B
HQY HealthEquity Inc

+0.59 (+0.62%)

USD 8.82B
TEM Tempus AI, Inc. Class A Common..

-0.12 (-0.34%)

USD 7.92B
WAY Waystar Holding Corp. Common S..

+0.83 (+2.25%)

USD 4.47B
BTSG BrightSpring Health Services, ..

+0.04 (+0.23%)

USD 3.18B
PRVA Privia Health Group Inc

-0.01 (-0.05%)

USD 2.52B
OMCL Omnicell Inc

-1.30 (-2.92%)

USD 2.13B
PINC Premier Inc

+0.13 (+0.61%)

USD 2.08B
WGS GeneDx Holdings Corp.

+1.00 (+1.31%)

USD 2.03B
GDRX Goodrx Holdings Inc

-0.03 (-0.66%)

USD 1.87B

ETFs Containing SDGR

ARKG ARK Genomic Revolution ET.. 4.21 % 0.75 %

+0.21 (+1.34%)

USD 1.04B
ARCG:LSE ARK Genomic Revolution UC.. 4.11 % 0.00 %

+3.98 (+1.34%)

USD 4.85M
ARKG:LSE ARK Genomic Revolution UC.. 4.11 % 0.00 %

+0.06 (+1.34%)

USD 4.85M
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.07 (+1.34%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.89% 37% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.89% 37% F 20% F
Trailing 12 Months  
Capital Gain -46.83% 34% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.83% 34% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.27% 49% F 23% F
Dividend Return -8.27% 47% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.98% 44% F 36% F
Risk Adjusted Return -15.33% 49% F 25% F
Market Capitalization 1.52B 75% C 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.